Bayesian Network Meta-Analysis of Targeted Therapies for Advanced Thyroid Cancer

A systematic review and Bayesian network meta-analysis of 9 randomized controlled trials involving 1,760 patients with metastatic or advanced radioiodine-refractory differentiated thyroid cancer. The dataset, published by Pin Wang on figshare, compares the efficacy and safety of targeted therapies like lenvatinib, anlotinib, apatinib, and cabozantinib based on outcomes including progression-free survival and objective response rate. The analysis was registered with PROSPERO (CRD420251089713) and the dataset was last updated in March 2026.

Use Cases

• Compare the progression-free survival benefit of different tyrosine kinase inhibitors based on reported hazard ratios.
• Rank treatments for safety by analyzing the reported surface under the cumulative ranking curve (SUCRA) values for grade ≥3 adverse events.
• Evaluate time-dependent efficacy patterns of therapies like apatinib based on the described waning benefit beyond 6–9 months.
• Assess the objective response rate of treatments using the reported odds ratios and SUCRA rankings.

Strengths

• Analysis is based on 9 randomized controlled trials, a standard for clinical evidence.
• Includes data from 1,760 patients, providing a substantial sample for the meta-analysis.
• Uses Bayesian network meta-analysis, a sophisticated statistical method for comparing multiple treatments.
• Reports specific statistical measures like hazard ratios, odds ratios, and SUCRA values for multiple endpoints.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for certain analytical tasks.
• The dataset is very small at 43.0 KB, indicating limited raw data scope.

Provenance

Source

figshare, author Pin Wang.

Collection Method

Systematic search of six electronic databases and subsequent Bayesian network meta-analysis.

Freshness

Last updated 2026-03-18 07:35:09